Clovis Oncology (CLVS) Shares are Up 17.36%

Clovis Oncology (CLVS) : Traders are bullish on Clovis Oncology (CLVS) as it has outperformed the S&P 500 by a wide margin of 92% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 16.74%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 17.36% in the last 1 week, and is up 88.12% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 34.16% and the 50-Day Moving Average is 72.88%.The 200 Day SMA reached 64.71% Clovis Oncology, Inc. is up 141.08% in the last 3-month period. Year-to-Date the stock performance stands at -7.29%.


Clovis Oncology (CLVS) : The highest short term price target forecast on Clovis Oncology (CLVS) is $30 and the lowest target price is $14. A total of 6 equity analysts are currently covering the company. The average price of all the analysts is $24.83 with a standard deviation of $6.46.

For the current week, the company shares have a recommendation consensus of Buy. Clovis Oncology (NASDAQ:CLVS): The stock opened at $30.49 and touched an intraday high of $32.63 on Friday. During the day, the stock corrected to an intraday low of $30.14, however, the bulls stepped in and pushed the price higher to close in the green at $32.45 with a gain of 5.94% for the day. The total traded volume for the day was 4,654,488. The stock had closed at $32.45 in the previous trading session.

Clovis Oncology, Inc. (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase (PARP), is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *